Cytokine profiles during infliximab monotherapy in psoriatic arthritis

British Journal of Dermatology

Volumn 153, Issue 3, 2005, Pages 531-536

  Mastroianni, A ^a   Minutilli, E ^a   Mussi, A ^a   Bordignon, V ^a   Trento, E ^a   D'Agosto, G ^a   Cordiali Fei, P ^a   Berardesca, Enzo ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

Cytokines; Infliximab; Interleukin 6; Matrix metalloproteinase 2; Psoriasis; Tumour necrosis factor alpha

Indexed keywords

CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; FIBROBLAST GROWTH FACTOR; GELATINASE A; INFLIXIMAB; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VASCULOTROPIN;

ADULT; ALLERGIC URTICARIA; APOPTOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL ARTICLE; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOMODULATION; INFLAMMATION; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SKIN INFLAMMATION; SYNOVITIS;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; BIOLOGICAL RESPONSE MODIFIERS; CYTOKINES; DRUG ADMINISTRATION SCHEDULE; E-SELECTIN; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INTERLEUKIN-6; JOINTS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; SKIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 24344505083     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06648.x     Document Type: Article

References (25)

1. Salvarani C, Cantini F, Olivieri I. Disease-modifying antirheumatic drug therapy for psoriatic arthritis. Clin Exp Rheumatol 2002; 20 (Suppl. 28):S71-5.
2. Mazzanti G, Coloni L, De Sabbata G, Paladini G. Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis: a pilot study. Acta Derm Venereol Suppl 1994; 186:116-17.
3. Scarpa R, Manguso F, Oriente F et al. Leflunomide in psoriatic poly-arthritis: an Italian pilot study. Arthritis Rheum 2001; 44 (Suppl.):S92.
4. Liang GC, Barr WG. Long term follow-up of the use of leflunomide in recalcitrant psoriatic arthritis and psoriasis. Arthritis Rheum 2001; 44 (Suppl.):S121.
5. Griffiths CE. Immunotherapy for psoriasis: from serendipity to selectivity. Lancet 2002; 359:279-80.
6. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345:248-55.
7. Dinant HJ, van Kuijk AWR, Goedkoop AY et al. Alefacept reduces synovial inflammatory infiltrate and improves outcome in psoriatic arthritis. Arthritis Rheum 2001; 42 (Suppl.):S91.
8. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418-26.
9. Partsch G, Steiner G, Leeb BF et al. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24:518-23.
10. Ettehadi P, Greaves MW, Wallach D et al. Elevated TNFα biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96:146-51.
11. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol 1999; 38:241-51.
12. Felson DT, Anderson JJ, Lange ML et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998; 41:1564-70.
13. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51:563-9.
14. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385-90.
15. Antoni C, Manger B. Infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol 2002; 20 (Suppl. 28):S122-5.
16. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357:1842-7.
17. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345:1098-104.
18. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-TNF α therapy for inflammatory arthritides. Arthritis Rheum 2001; 44:2862-9.
19. Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124:1774-85.
20. Di Sabatino A, Ciccocioppo R, Cinque B et al. Defective mucosal T cell death is substantially reverted by infiximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53:70-7.
21. Sagawa Y, Shiohara T, Imanishi K, Nagashima M. Is sustained production of tumor necrosis factor-alpha relevant to the development of pustular psoriasis? Dermatology 1993; 187:81-3.
22. Mease PJ. TNF in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002; 61:298-304.
23. Danning CL, Illei GG, Hitchon C et al. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000; 43:1244-56.
24. Austin LM, Ozawa M, Kikuchi T et al. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999; 113:752-9.
25. Fleischmajer R, Kuroda K, Hazan R et al. Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2. J Invest Dermatol 2000; 115:771-7.